What are the common adverse reactions of medroxyprogesterone acetate therapy in adolescents?

Common Adverse Reactions of Medroxyprogesterone Therapy in Teenagers

The most common adverse reactions of depot medroxyprogesterone acetate (DMPA) in adolescents are menstrual irregularities (present in nearly all patients initially), weight gain, headache, and decreased bone mineral density. 1, 2

Primary Adverse Effects

Menstrual Irregularities

• Nearly universal initially - present in almost all adolescent patients at the start of therapy 1, 2
• Typically includes irregular bleeding, spotting, or prolonged bleeding
• Improves over time - 30-40% of adolescents experience amenorrhea by later injection cycles 2
• Bleeding patterns average 8-13 days between injections for those who continue to bleed 3
• Pre-injection counseling about these effects significantly reduces discontinuation rates 1

Weight Gain

• Significant and well-documented in adolescents 1, 2, 4
• Average weight gain: 6.0 kg at 11 months and 9.0 kg at 17 months of use 2
• 21% of adolescents experience early excessive weight gain (>5% increase at 6 months), which strongly predicts continued excessive weight gain 2
• Early gainers experience mean BMI increase of 7.6 compared to 2.3 for non-early gainers over 18 months 2
• Reported by 27% of adolescent users as a perceived side effect 3

Bone Mineral Density Loss

• DMPA causes reductions in BMD at both lumbar spine and femoral neck 1, 5
• FDA issued black-box warning in 2004 regarding decreased BMD risk 1
• In adolescents over 12 months: lumbar spine BMD decreased by mean of -1.4% and femoral neck BMD decreased by -2.2% 5
• Substantially reversible after discontinuation 1
• ACOG does not recommend limiting use to 2 years or routine bone density monitoring 1

Secondary Adverse Effects

Neurological and Mood

• Headache: reported by 25% of adolescent users 1, 3
• Mood changes: inconsistent evidence exists, but one prospective study found no significant depressive symptoms over 12 months using validated scales 6
• Fatigue/weakness: reported by 23% of users 3

Other Common Effects

• Mastalgia (breast tenderness) 1
• Hair loss 1
• Change in libido (decreased sexual desire reported by 15% of adolescents) 1, 3
• Abdominal pain: reported by 18% of users 3

Serious but Rare Adverse Effects

Per FDA labeling 7:

• Anaphylaxis and anaphylactoid reactions (postmarketing reports)
• Thromboembolic disorders (thrombophlebitis, pulmonary embolism, cerebrovascular disorders)
• Osteoporotic fractures (rare postmarketing cases)
• Ectopic pregnancy risk if pregnancy occurs
• Possible increased risk of breast cancer in subpopulation with first exposure <35 years and within previous 4 years (RR 2.19) 7

Important Clinical Considerations

Delayed Return to Fertility

• Typical delay of 9-18 months after discontinuation 2
• Usually not a major deterrent for adolescent patients 2

Counseling Recommendations

All adolescent patients should receive counseling on 1, 2, 4:

• Calcium supplementation: 1300 mg daily
• Vitamin D supplementation: 600 IU daily
• Regular weight-bearing exercise
• Smoking cessation (if applicable)
• Expected menstrual changes and timeline for improvement

Monitoring Strategy

• Weight monitoring at 6 months is critical - weight gain >5% at 6 months strongly predicts excessive long-term weight gain 2
• Consider alternative contraception for early excessive weight gainers
• No routine bone density monitoring recommended unless additional risk factors present 1, 4

The evidence consistently demonstrates that while DMPA has significant adverse effects in adolescents, particularly menstrual irregularities and weight gain, 87% of adolescent users report satisfaction with the method 3, and it remains highly effective with no pregnancies reported in adolescent cohorts when used correctly 3.